GroundForce Capital has announced a significant growth investment in Signum Dermalogix Inc., the parent company of the professional skincare brand Epicutis. This strategic funding is earmarked to accelerate the brand's expansion within the professional dermocosmetics market. While the specific financial terms of the transaction were not disclosed, the investment marks a new chapter of growth for the science-backed company.
A Foundation in Bioscience
Epicutis distinguishes itself through a deep-rooted connection to over two decades of bioscience research affiliated with Princeton University. The brand's formulations are built upon proprietary, patent-protected active ingredients such as TSC, DSD, and HYVIA®. This scientific foundation allows the company to offer clean, minimalist skincare products that prioritize efficacy and skin health.
Strategic Growth in the Professional Channel
The company has demonstrated remarkable commercial success, achieving a compound annual growth rate of nearly 100% over the past two years. This rapid expansion is supported by a network of over 4,100 active professional accounts across the nation. Epicutis has strategically focused on medspas, dermatology practices, and luxury spas, where practitioner endorsements are a key driver of consumer trust.
Fueling Future Innovation and Expansion
With this new infusion of capital, Epicutis plans to bolster its market position significantly. The funds will be allocated toward increasing brand awareness, advancing its research and development pipeline, and launching new innovative products. This investment will enable the company to build upon its current momentum and meet the growing demand for clinically validated skincare solutions.
Maxwell Stock, the company's co-founder and CEO, emphasized that the brand was founded on the principle of scientific validation before products reach consumers. He stated that the partnership with GroundForce will accelerate investment in the product discovery pipeline. This collaboration aims to solidify Epicutis's leadership role within the professional skincare market.
Investor Confidence and Strategic Partnership
GroundForce Capital identified Epicutis as a compelling opportunity due to its unique blend of proprietary science and effective commercial strategy. The investment firm was particularly impressed by the brand's ability to build a differentiated platform while earning trust within the professional community. As part of the agreement, a representative from GroundForce Capital will join the Epicutis board of directors.
Dan Gluck, Co-Founder and Co-Managing Partner of GroundForce Capital, praised the company's rare achievement in the competitive skincare industry. He highlighted the team's disciplined approach to earning practitioner trust one account at a time. The investment firm is committed to supporting this strategy as Epicutis scales its professional distribution network for its next growth phase.
This strategic partnership between Epicutis and GroundForce Capital signals a pivotal moment for the science-driven skincare brand. The investment not only validates the company's unique market approach but also provides the necessary resources to enhance its product innovation and expand its professional footprint. As consumer demand for expert-recommended, clinically-backed products continues to rise, Epicutis is now strongly positioned to lead the next wave of growth in dermocosmetics.